Concepts (254)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mammaplasty | 21 | 2025 | 116 | 9.160 |
Why?
|
| Adipose Tissue | 21 | 2024 | 265 | 7.390 |
Why?
|
| Breast Neoplasms | 26 | 2025 | 3033 | 3.310 |
Why?
|
| Transplantation, Autologous | 16 | 2022 | 351 | 2.550 |
Why?
|
| Mastectomy | 12 | 2025 | 254 | 2.110 |
Why?
|
| Mastectomy, Segmental | 5 | 2023 | 101 | 1.890 |
Why?
|
| Breast Implants | 5 | 2020 | 27 | 1.810 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 5 | 2013 | 61 | 1.490 |
Why?
|
| Adipocytes | 3 | 2022 | 169 | 1.480 |
Why?
|
| Venous Thrombosis | 3 | 2018 | 255 | 1.470 |
Why?
|
| Lymphedema | 2 | 2022 | 79 | 1.380 |
Why?
|
| Breast | 9 | 2022 | 289 | 1.300 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 4 | 2020 | 9 | 1.260 |
Why?
|
| Anastomosis, Surgical | 3 | 2018 | 278 | 1.230 |
Why?
|
| Postoperative Complications | 8 | 2025 | 2349 | 1.210 |
Why?
|
| Upper Extremity | 1 | 2025 | 57 | 0.910 |
Why?
|
| Free Tissue Flaps | 4 | 2021 | 50 | 0.900 |
Why?
|
| Tissue and Organ Harvesting | 3 | 2021 | 80 | 0.900 |
Why?
|
| Humans | 62 | 2025 | 91231 | 0.870 |
Why?
|
| Tissue Scaffolds | 3 | 2014 | 123 | 0.850 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2025 | 215 | 0.830 |
Why?
|
| Fat Necrosis | 1 | 2022 | 6 | 0.810 |
Why?
|
| Face | 1 | 2022 | 118 | 0.770 |
Why?
|
| Microsurgery | 4 | 2022 | 93 | 0.770 |
Why?
|
| Tissue Engineering | 5 | 2021 | 199 | 0.720 |
Why?
|
| Female | 38 | 2025 | 47282 | 0.710 |
Why?
|
| Wound Healing | 3 | 2013 | 365 | 0.710 |
Why?
|
| Ki-1 Antigen | 1 | 2020 | 19 | 0.680 |
Why?
|
| Lipectomy | 1 | 2019 | 9 | 0.640 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 375 | 0.630 |
Why?
|
| Patient Education as Topic | 1 | 2021 | 368 | 0.610 |
Why?
|
| Acellular Dermis | 1 | 2018 | 5 | 0.600 |
Why?
|
| Tissue Expansion | 1 | 2018 | 19 | 0.600 |
Why?
|
| Breast Implantation | 1 | 2018 | 14 | 0.590 |
Why?
|
| Mass Screening | 1 | 2022 | 646 | 0.570 |
Why?
|
| Middle Aged | 19 | 2024 | 26616 | 0.540 |
Why?
|
| Macrophages | 4 | 2013 | 591 | 0.540 |
Why?
|
| Abdominal Fat | 2 | 2013 | 13 | 0.540 |
Why?
|
| Immunophenotyping | 3 | 2013 | 218 | 0.540 |
Why?
|
| Hydrogel, Polyethylene Glycol Dimethacrylate | 2 | 2013 | 31 | 0.480 |
Why?
|
| Bone Marrow Cells | 2 | 2013 | 263 | 0.470 |
Why?
|
| Hyaluronic Acid | 2 | 2013 | 52 | 0.470 |
Why?
|
| Prospective Studies | 8 | 2022 | 4374 | 0.450 |
Why?
|
| Immunomodulation | 1 | 2014 | 58 | 0.450 |
Why?
|
| Adult | 19 | 2024 | 27212 | 0.430 |
Why?
|
| Skin | 3 | 2019 | 589 | 0.420 |
Why?
|
| Biocompatible Materials | 1 | 2014 | 198 | 0.410 |
Why?
|
| Retrospective Studies | 14 | 2022 | 9400 | 0.400 |
Why?
|
| Perforator Flap | 2 | 2022 | 12 | 0.390 |
Why?
|
| Autografts | 3 | 2021 | 30 | 0.390 |
Why?
|
| Cell Lineage | 1 | 2013 | 297 | 0.390 |
Why?
|
| Tracheal Diseases | 1 | 2010 | 14 | 0.350 |
Why?
|
| Laryngeal Diseases | 1 | 2010 | 20 | 0.350 |
Why?
|
| Aged | 14 | 2021 | 19603 | 0.350 |
Why?
|
| Surgical Flaps | 3 | 2025 | 254 | 0.350 |
Why?
|
| Time and Motion Studies | 2 | 2021 | 21 | 0.340 |
Why?
|
| Filtration | 2 | 2021 | 27 | 0.340 |
Why?
|
| Vocal Cords | 1 | 2010 | 27 | 0.340 |
Why?
|
| Seroma | 2 | 2020 | 7 | 0.320 |
Why?
|
| Propensity Score | 2 | 2021 | 155 | 0.320 |
Why?
|
| Follow-Up Studies | 9 | 2020 | 3723 | 0.310 |
Why?
|
| Skin Diseases | 1 | 2010 | 174 | 0.290 |
Why?
|
| Surgery, Plastic | 2 | 2021 | 42 | 0.270 |
Why?
|
| Cell Survival | 2 | 2024 | 985 | 0.270 |
Why?
|
| Flow Cytometry | 4 | 2013 | 696 | 0.270 |
Why?
|
| Fibroblasts | 1 | 2010 | 768 | 0.270 |
Why?
|
| Wounds and Injuries | 1 | 2010 | 271 | 0.260 |
Why?
|
| Time Factors | 6 | 2020 | 5385 | 0.260 |
Why?
|
| Stem Cells | 2 | 2024 | 382 | 0.260 |
Why?
|
| Head and Neck Neoplasms | 3 | 2019 | 1086 | 0.250 |
Why?
|
| Neoplasms | 1 | 2021 | 3060 | 0.250 |
Why?
|
| Coculture Techniques | 4 | 2013 | 177 | 0.250 |
Why?
|
| Cells, Cultured | 6 | 2013 | 2893 | 0.240 |
Why?
|
| Patient Preference | 2 | 2023 | 119 | 0.230 |
Why?
|
| Axilla | 1 | 2024 | 104 | 0.220 |
Why?
|
| Cell Differentiation | 5 | 2013 | 1568 | 0.210 |
Why?
|
| Young Adult | 6 | 2021 | 6521 | 0.210 |
Why?
|
| Treatment Outcome | 5 | 2022 | 8428 | 0.200 |
Why?
|
| Lymph Node Excision | 1 | 2024 | 223 | 0.200 |
Why?
|
| Mammary Arteries | 1 | 2022 | 34 | 0.200 |
Why?
|
| Trauma Centers | 2 | 2015 | 158 | 0.200 |
Why?
|
| Shoulder | 1 | 2022 | 43 | 0.190 |
Why?
|
| Dietary Supplements | 1 | 2022 | 124 | 0.190 |
Why?
|
| Cytokines | 2 | 2024 | 824 | 0.190 |
Why?
|
| Myocutaneous Flap | 1 | 2021 | 5 | 0.190 |
Why?
|
| Arm | 1 | 2022 | 100 | 0.190 |
Why?
|
| Patient Satisfaction | 2 | 2022 | 465 | 0.190 |
Why?
|
| Community Participation | 1 | 2021 | 38 | 0.190 |
Why?
|
| Embolism, Fat | 1 | 2021 | 2 | 0.190 |
Why?
|
| Centrifugation | 1 | 2021 | 24 | 0.190 |
Why?
|
| Drainage | 1 | 2022 | 169 | 0.180 |
Why?
|
| Lymphangiogenesis | 1 | 2021 | 40 | 0.180 |
Why?
|
| Clothing | 1 | 2020 | 7 | 0.170 |
Why?
|
| Rectus Abdominis | 2 | 2010 | 40 | 0.170 |
Why?
|
| Cadaver | 2 | 2018 | 187 | 0.170 |
Why?
|
| Physicians, Women | 1 | 2020 | 59 | 0.170 |
Why?
|
| Aged, 80 and over | 6 | 2021 | 6844 | 0.160 |
Why?
|
| Nipples | 1 | 2019 | 37 | 0.160 |
Why?
|
| Organ Sparing Treatments | 1 | 2019 | 47 | 0.160 |
Why?
|
| Quality of Life | 3 | 2022 | 1706 | 0.160 |
Why?
|
| Skin Transplantation | 2 | 2010 | 187 | 0.160 |
Why?
|
| Subcutaneous Fat | 1 | 2018 | 22 | 0.150 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 126 | 0.150 |
Why?
|
| Freeze Drying | 1 | 2018 | 15 | 0.150 |
Why?
|
| Operating Rooms | 1 | 2019 | 125 | 0.150 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2018 | 36 | 0.150 |
Why?
|
| Endothelial Cells | 1 | 2021 | 472 | 0.150 |
Why?
|
| Graft Survival | 2 | 2021 | 921 | 0.140 |
Why?
|
| Education, Medical | 1 | 2020 | 244 | 0.140 |
Why?
|
| Microvessels | 1 | 2017 | 70 | 0.140 |
Why?
|
| Treatment Failure | 1 | 2018 | 284 | 0.140 |
Why?
|
| Epinephrine | 1 | 2017 | 88 | 0.140 |
Why?
|
| Lidocaine | 1 | 2017 | 66 | 0.140 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2021 | 539 | 0.140 |
Why?
|
| Suture Techniques | 1 | 2017 | 143 | 0.130 |
Why?
|
| Anesthetics, Local | 1 | 2017 | 79 | 0.130 |
Why?
|
| Surgeons | 1 | 2020 | 254 | 0.130 |
Why?
|
| Esthetics | 2 | 2020 | 45 | 0.130 |
Why?
|
| Pilot Projects | 1 | 2019 | 890 | 0.130 |
Why?
|
| Mammography | 1 | 2019 | 470 | 0.130 |
Why?
|
| Surgical Wound Infection | 1 | 2018 | 206 | 0.130 |
Why?
|
| Male | 9 | 2021 | 43371 | 0.120 |
Why?
|
| Patient Readmission | 1 | 2019 | 367 | 0.120 |
Why?
|
| Students, Medical | 1 | 2020 | 427 | 0.120 |
Why?
|
| Facial Injuries | 1 | 2015 | 20 | 0.120 |
Why?
|
| Quality Improvement | 1 | 2019 | 460 | 0.120 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 2787 | 0.120 |
Why?
|
| Pain, Postoperative | 1 | 2017 | 259 | 0.120 |
Why?
|
| Foreign-Body Reaction | 1 | 2014 | 12 | 0.120 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2015 | 114 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2021 | 1378 | 0.110 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2015 | 291 | 0.110 |
Why?
|
| Clinical Protocols | 1 | 2014 | 158 | 0.110 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2013 | 16 | 0.110 |
Why?
|
| Forkhead Transcription Factors | 1 | 2014 | 173 | 0.110 |
Why?
|
| Gelatin | 1 | 2013 | 26 | 0.110 |
Why?
|
| Reoperation | 2 | 2019 | 611 | 0.110 |
Why?
|
| Swine, Miniature | 1 | 2013 | 50 | 0.110 |
Why?
|
| Cell Separation | 1 | 2013 | 200 | 0.100 |
Why?
|
| Sus scrofa | 1 | 2013 | 51 | 0.100 |
Why?
|
| Internship and Residency | 2 | 2020 | 1073 | 0.100 |
Why?
|
| Neoplastic Stem Cells | 1 | 2014 | 165 | 0.100 |
Why?
|
| Fibroblast Growth Factors | 1 | 2013 | 82 | 0.100 |
Why?
|
| Device Removal | 2 | 2013 | 161 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2015 | 2709 | 0.100 |
Why?
|
| Adolescent | 3 | 2021 | 9434 | 0.100 |
Why?
|
| Epidermis | 1 | 2013 | 102 | 0.100 |
Why?
|
| Cell Communication | 1 | 2013 | 204 | 0.100 |
Why?
|
| Surgicenters | 1 | 2011 | 5 | 0.100 |
Why?
|
| Mannose-Binding Lectins | 1 | 2011 | 6 | 0.090 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2011 | 23 | 0.090 |
Why?
|
| HLA-DR Antigens | 1 | 2011 | 59 | 0.090 |
Why?
|
| Antigens, CD | 1 | 2013 | 473 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 888 | 0.090 |
Why?
|
| Swine | 1 | 2013 | 600 | 0.090 |
Why?
|
| Maxillofacial Injuries | 1 | 2011 | 4 | 0.090 |
Why?
|
| Receptors, IgG | 1 | 2011 | 55 | 0.090 |
Why?
|
| Skull Fractures | 1 | 2011 | 26 | 0.090 |
Why?
|
| Lectins, C-Type | 1 | 2011 | 86 | 0.090 |
Why?
|
| Respiration, Artificial | 1 | 2014 | 376 | 0.090 |
Why?
|
| Interdisciplinary Communication | 1 | 2011 | 130 | 0.090 |
Why?
|
| Rejuvenation | 1 | 2010 | 21 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 1 | 2013 | 925 | 0.090 |
Why?
|
| Regenerative Medicine | 1 | 2010 | 26 | 0.090 |
Why?
|
| Cooperative Behavior | 1 | 2011 | 180 | 0.090 |
Why?
|
| Transplantation, Homologous | 1 | 2013 | 1008 | 0.090 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2010 | 62 | 0.080 |
Why?
|
| Monocytes | 1 | 2011 | 222 | 0.080 |
Why?
|
| Receptors, Cell Surface | 1 | 2011 | 289 | 0.080 |
Why?
|
| Adipogenesis | 1 | 2009 | 40 | 0.080 |
Why?
|
| MicroRNAs | 1 | 2014 | 570 | 0.080 |
Why?
|
| Academic Medical Centers | 1 | 2011 | 390 | 0.080 |
Why?
|
| Patient Care Team | 1 | 2011 | 292 | 0.080 |
Why?
|
| Monitoring, Physiologic | 1 | 2010 | 264 | 0.080 |
Why?
|
| Regeneration | 1 | 2010 | 157 | 0.080 |
Why?
|
| Cell Culture Techniques | 1 | 2009 | 198 | 0.080 |
Why?
|
| Islets of Langerhans | 1 | 2012 | 553 | 0.080 |
Why?
|
| In Vitro Techniques | 1 | 2010 | 997 | 0.080 |
Why?
|
| Disease Models, Animal | 2 | 2013 | 2435 | 0.080 |
Why?
|
| Cell Membrane | 1 | 2011 | 683 | 0.070 |
Why?
|
| Extracellular Matrix | 1 | 2009 | 248 | 0.070 |
Why?
|
| Gene Expression Regulation | 2 | 2013 | 1998 | 0.070 |
Why?
|
| Interferon-gamma | 1 | 2010 | 449 | 0.070 |
Why?
|
| Mutation | 1 | 2019 | 4210 | 0.070 |
Why?
|
| Glucose | 1 | 2010 | 631 | 0.070 |
Why?
|
| Phenotype | 1 | 2013 | 2489 | 0.070 |
Why?
|
| Biomarkers | 1 | 2013 | 1822 | 0.070 |
Why?
|
| Chronic Disease | 1 | 2010 | 963 | 0.070 |
Why?
|
| Prognosis | 3 | 2019 | 3829 | 0.060 |
Why?
|
| Animals | 3 | 2014 | 27853 | 0.060 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2024 | 80 | 0.060 |
Why?
|
| Ribs | 1 | 2022 | 46 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2022 | 105 | 0.050 |
Why?
|
| Lymphatic Metastasis | 1 | 2024 | 500 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2015 | 1173 | 0.050 |
Why?
|
| Buttocks | 1 | 2021 | 10 | 0.050 |
Why?
|
| Neoadjuvant Therapy | 1 | 2024 | 396 | 0.040 |
Why?
|
| Consensus | 1 | 2022 | 374 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2024 | 1718 | 0.040 |
Why?
|
| Lymph Nodes | 1 | 2024 | 554 | 0.040 |
Why?
|
| Survivorship | 1 | 2020 | 19 | 0.040 |
Why?
|
| Elasticity | 1 | 2019 | 102 | 0.040 |
Why?
|
| Cancer Survivors | 1 | 2020 | 66 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2020 | 158 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2024 | 2024 | 0.040 |
Why?
|
| Gene Expression | 2 | 2013 | 1314 | 0.040 |
Why?
|
| BRCA2 Protein | 1 | 2019 | 163 | 0.040 |
Why?
|
| Inpatients | 1 | 2021 | 320 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2018 | 152 | 0.040 |
Why?
|
| Biomechanical Phenomena | 1 | 2019 | 484 | 0.040 |
Why?
|
| Cell Line, Tumor | 2 | 2014 | 2627 | 0.040 |
Why?
|
| BRCA1 Protein | 1 | 2019 | 207 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2013 | 1695 | 0.030 |
Why?
|
| United States | 2 | 2021 | 7205 | 0.030 |
Why?
|
| Glasgow Coma Scale | 1 | 2015 | 77 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2017 | 805 | 0.030 |
Why?
|
| Ventilator Weaning | 1 | 2014 | 25 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 479 | 0.030 |
Why?
|
| Speech | 1 | 2014 | 87 | 0.030 |
Why?
|
| Drug Therapy | 1 | 2013 | 69 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 853 | 0.030 |
Why?
|
| Disease Management | 1 | 2015 | 337 | 0.030 |
Why?
|
| Watchful Waiting | 1 | 2013 | 69 | 0.030 |
Why?
|
| Child | 2 | 2015 | 7291 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2017 | 1744 | 0.030 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2013 | 128 | 0.030 |
Why?
|
| Carcinogenesis | 1 | 2014 | 217 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2013 | 183 | 0.020 |
Why?
|
| Antigens, Surface | 1 | 2012 | 103 | 0.020 |
Why?
|
| Capital Financing | 1 | 2011 | 4 | 0.020 |
Why?
|
| Fees, Medical | 1 | 2011 | 10 | 0.020 |
Why?
|
| Facility Design and Construction | 1 | 2011 | 5 | 0.020 |
Why?
|
| Group Practice | 1 | 2011 | 7 | 0.020 |
Why?
|
| Wisconsin | 1 | 2011 | 43 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2020 | 2699 | 0.020 |
Why?
|
| Incidence | 1 | 2016 | 1599 | 0.020 |
Why?
|
| Trauma Severity Indices | 1 | 2011 | 44 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2014 | 1501 | 0.020 |
Why?
|
| Length of Stay | 1 | 2014 | 761 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2014 | 415 | 0.020 |
Why?
|
| Logistic Models | 1 | 2014 | 1218 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2014 | 1070 | 0.020 |
Why?
|
| Veins | 1 | 2010 | 95 | 0.020 |
Why?
|
| Constriction, Pathologic | 1 | 2010 | 220 | 0.020 |
Why?
|
| Arteries | 1 | 2010 | 178 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2015 | 2516 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2014 | 1302 | 0.020 |
Why?
|
| Risk Factors | 1 | 2019 | 5609 | 0.020 |
Why?
|
| Infant | 1 | 2015 | 3207 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2015 | 3793 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2013 | 1473 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2010 | 1230 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2014 | 1564 | 0.020 |
Why?
|
| Rats | 1 | 2010 | 4060 | 0.010 |
Why?
|